Drugs / LY2510924
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02737072 | Sep 2016 → Sep 2017 | cancer | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT02652871 | May 2016 → Jul 2019 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT01439568 | Sep 2011 → Jan 2014 | small cell lung carcinoma | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT01391130 | Aug 2011 → Sep 2014 | clear cell renal carcinoma | Eli Lilly and Company | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2510924 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01439568 ↗ |
| Action | Inhibit | “antagonist of CXCR4” PMID 27154357 ↗ Oct 2016 |
| Modality | Peptide | “a peptide antagonist of CXCR4” PMID 27154357 ↗ Oct 2016 |
| Route | Subcutaneous | “Administered subcutaneously” NCT01391130 ↗ |
| Target | CXCR4 | “antagonist of CXCR4” PMID 27154357 ↗ Oct 2016 |